Abstract
BackgroundPartial ablation of the prostate using high-intensity focussed ultrasound (HIFU-PA) is a treatment option for localised prostate cancer. When local recurrence occurs, salvage robot-assisted radical prostatectomy is a treatment option for selected patients, but there is a paucity of data on the peri-operative safety, functional and oncologic outcomes of sRARP..The objective of this study was therefore to describe peri-operative safety, functional and early oncologic outcomes following salvage robot-assisted radical prostatectomy (sRARP) for local recurrence after HIFU-PA.MethodsRetrospective analysis of a prospective database of 53 consecutive men who underwent sRARP after HIFU-PA from 2012 to 2018. Continence and erectile-function were reported pre-HIFU, pre-sRARP, 3-months post-sRARP and 12-months post-sRARP. Complications, PSMs and need for subsequent ADT/radiotherapy were assessed.Results45 men were suitable for inclusion and had sufficient data for analyses. Median duration from HIFU to sRARP was 30.0 months and median follow-up post-sRARP was 17.7 months. Median age, PSA and ISUP group were 63.0 yrs., 7.2 ng/mL and 2; 88.9% were cT2.Median operative-console time, blood loss and hospital stay were 140 min, 200 ml and 1 day respectively. Clavien-Dindo grade 1, 2 and 3 complications < 90 days occurred in 8.9, 6.7 and 2.2%; late (>90d) complications occurred in 13.2%.At sRARP pathology, ISUP 3–5 occurred in 51.1%, pT3a/b in 64.5%, and PSMs in 44.4% (37.5% for pT2, 48.3% for pT3).Of men with > 3-months follow-up after sRARP, 26.3% underwent adjuvant radiotherapy/ADT for residual disease or adverse pathologic features; 5.3% experienced BCR requiring salvage ADT/radiotherapy. Freedom from ADT/radiotherapy was 66.7% at 12-months.Pad-free rates were 100% pre-HIFU, 95.3% post-HIFU, 29.4% 3-months post-sRARP, and 65.5% 12-months post-sRARP. Median IIEF-5 scores pre-HIFU, post-HIFU, 3- and 12-months post-sRARP were 23.5, 16, 5 and 5, respectively. Potency rates were 81.8, 65.5, 0 and 0%, respectively. Bilateral/unilateral nerve sparing were feasible in 7%/22%.ConclusionSalvage RARP was safe with acceptable but sub-optimal continence and poor sexual-function and poor oncologic outcomes. One in three men required additional treatment within 12-months. This information may aid men and urologists with treatment selection and counselling regarding primary HIFU-PA vs primary RARP and when considering salvage RARP.
Highlights
Partial ablation of the prostate using high-intensity focussed ultrasound (HIFU-Partial Ablation (PA)) is a treatment option for localised prostate cancer
There is very little published data on outcomes for salvage RARP after High-Intensity Focussed Ultrasound – Partial Ablation (HIFU-PA). salvage robot-assisted radical prostatectomy (sRARP) after radiotherapy is associated with adverse pathologic features, high Positive Surgical Margin (PSM) rates, low continence rates, poor erectile function and higher anastomotic leak/stricture rates compared to primary RARP [8,9,10]
CLINICO-PATHOLOGIC CHARACTERISTICS Clinico-pathologic characteristics pre-High-intensity focused ultrasound (HIFU), pre-sRARP and post-sRARP are shown in Table 1 including age, PSA, Gleason sum, cancer volume and cT-stage
Summary
Partial ablation of the prostate using high-intensity focussed ultrasound (HIFU-PA) is a treatment option for localised prostate cancer. Salvage robot-assisted radical prostatectomy is a treatment option for selected patients, but there is a paucity of data on the peri-operative safety, functional and oncologic outcomes of sRARP. The objective of this study was to describe peri-operative safety, functional and early oncologic outcomes following salvage robot-assisted radical prostatectomy (sRARP) for local recurrence after HIFU-PA. SRARP after radiotherapy is associated with adverse pathologic features, high PSM rates, low continence rates, poor erectile function and higher anastomotic leak/stricture rates compared to primary RARP [8,9,10]. After PA, Nunes-Silva et al reported similar continence but worse sexual function and higher recurrence rates for sRARP compared to primary RARP in a matched-pair analysis [11]. Marconi et al recently reported on their cohort of 82 men undergoing sRARP after FA by two surgeons in which they demonstrated safety and feasibility as well as impressive 83% pad-free continence at 1 year; potency was low (14% at 1 year) and the incidence of BCR was high (64% at 3years) [12]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.